August 25, 2025

What Does Xlear’s Lawsuit Mean for Physicians?

Xlear's xylitol maker sues the FTC to loosen evidence rules on health claims, signaling a deregulatory push that could reshape supplement marketing.

KFF Health News

August 18, 2025

FDA Approves New Indication for Wegovy

Accelerated approval granted to Wegovy for treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis in adults with stage F2 to F3 fibrosis.

Conexiant

August 11, 2025

FDA OKs Bioequivalent Iron Sucrose for CKD Anemia

The FDA has approved a bioequivalent iron sucrose injection for treating iron deficiency anemia in patients with chronic kidney disease.

Conexiant

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant

August 01, 2024

Tirzepatide Reduces Heart Failure Risk by 38% in Clinical Trial

Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.

Reuters

July 25, 2024

Senate Investigates Bankruptcy of Hospital Chain: CEO Subpoenaed

The U.S. Senate Committee is calling the CEO of Steward Health to testify about alleged corporate greed and financial mismanagement amid the company's bankruptcy.

Reuters

September 09, 2024

FDA Lifts Hold on Low Blood Sugar Treatment

Rezolute Inc has received FDA approval to proceed with its late-stage trial for a new treatment addressing low blood sugar in individuals with congenital hyperinsulinism, with potential U.S. enrollment expected to start in early 2025.

Reuters

November 15, 2024

RFK Jr.'s Vision for U.S. Food and Drug System Reform

The FDA's nutrition department has to go: "They're not doing their job. They're not protecting our kids."

Reuters